Waves of Knowledge
Explore insights
I am a neuroscientist and physician-researcher drawn, almost inexorably, to one of the most urgent enigmas of our age: the origins and unfolding course of Alzheimer’s disease. It is a puzzle that resists easy answers, that slips through the nets of neat theories, that humbles even the most rigorous of minds. Over the years, I have written twenty-seven peer-reviewed papers, each a fragment in a larger mosaic, each an attempt to reimagine how we approach the silent devastation of neurodegeneration.
My research has wandered deliberately across scales—from molecules shimmering in the biochemical dark, to pathways winding through the cell, to the lived realities of patients and their families. For Alzheimer’s refuses to remain confined; it is not a single narrative but a chorus of dissonant voices. For too long the field has placed its faith in amyloid plaques and tau tangles, as if two actors alone could account for the breadth of this tragedy. I have argued, instead, for a wider frame: that Alzheimer’s is not one story but many, a disorder of intricacy and entanglement, a tapestry in which countless threads are woven and unraveled at once.
My Central Hypothesis
At the heart of my work lies a conviction both unsettling and clarifying: Alzheimer’s cannot be reduced to the familiar images in the textbooks—the plaques and tangles that have long dominated our imagination. They are visible, yes, and dramatic, but they are also incomplete. The evidence points elsewhere: to a deeper, more turbulent current of metabolic dysfunction, oxidative stress, and systemic imbalance, beginning years—often decades—before the first faint tremors of memory loss.
I have proposed that severe metabolic collapse, especially disruptions in arginine and branched-chain amino acid pathways, is not a bystander but a prime mover. Oxidative stress, in this telling, is both cause and consequence—a cruel cycle that gnaws at the brain’s foundations. Within this framework, amyloid and tau appear not as villains in their own right, but as the remnants of battle, the scars left upon the landscape of a body already faltering.
This perspective alters the horizon of therapy. If the disease is larger than the plaques, then our strategies must be larger still. We must think not only of protein aggregation but of neuronal death, inflammation, DNA injury, mitochondrial exhaustion, the very collapse of energy metabolism. These are not peripheral echoes but central players. And if we can learn to intervene early—at the level of these fundamental processes—then perhaps we may not only treat but prevent, offering a different fate before the illness has stolen too much.
Dr. Baruh Polis, MD, PhD
Science
A New Perspective on Alzheimer’s Disease as a Brain Expression of a Complex Metabolic Disorder
Alzheimer’s disease (AD) is an irredeemable chronic neurodegenerative disorder and the predominant cause of dementia. The disease progression is associated with the deposition of amyloid plaques and formation of neurofibrillary tangles in the brain, yet clinical dementia is the end and culminating stage of the enduring pathology. Recent evidence suggests that AD is characterized by distinctive abnormalities apparent on systemic, histological, macromolecular, and biochemical levels. Besides the well-described characteristic profuse neurofibrillary tangles, dystrophic neurites, and Aβ deposits, the AD pathology includes substantial neuronal loss, inflammation, extensive DNA damage, considerable mitochondrial malfunction, impaired energy metabolism, and chronic oxidative stress. Moreover, severe metabolic dysfunction leading to oxidative stress is a possible cause and hallmark of AD that is apparent decades before the disease manifestation. State-of-the-art metabolomics studies have proved that arginine and branched-chain amino acids metabolism disturbances accompany AD and contribute to its pathogenesis. Repetitive failures to find an efficient anti-amyloid or anti-Tau treatment, which would face the challenges of the complex AD pathology, led to the hypothesis that hyperphosphorylated Tau and deposited Aβ proteins are hallmarks, not the ultimate causes of AD. Accordingly, the modern scientific vision of AD etiology and pathogenesis must reach beyond the hallmarks and look for alternative strategies and areas of research
Alzheimer’s disease as a chronic maladaptive polyamine stress response
Polyamines are nitrogen-rich polycationic ubiquitous bioactive molecules with diverse evolutionary-conserved functions. Their activity interferes with numerous genes' expression resulting in cell proliferation and signaling modulation.
The intracellular levels of polyamines are precisely controlled by an evolutionary-conserved machinery. Their transient synthesis is induced by heat stress, radiation, and other traumatic stimuli in a process termed the polyamine stress response (PSR).
Notably, polyamine levels decline gradually with age; and external supplementation improves lifespan in model organisms. This corresponds to cytoprotective and reactive oxygen species scavenging properties of polyamines. Paradoxically, age-associated neurodegenerative disorders are characterized by upsurge in polyamines levels, indicating polyamine pleiotropic, adaptive, and pathogenic roles. Specifically, arginase overactivation and arginine brain deprivation have been shown to play an important role in Alzheimer’s disease (AD) pathogenesis.
Here, we assert that a universal short-term PSR associated with acute stimuli is beneficial for survival. However, it becomes detrimental and maladaptive following chronic noxious stimuli, especially in an aging organism. Furthermore, we regard cellular senescence as an adaptive response to stress and suggest that PSR plays a central role in age-related neurodegenerative diseases' pathogenesis.
Our perspective on AD proposes an inclusive reassessment of the causal relationships between the classical hallmarks and clinical manifestation. Consequently, we offer a novel treatment strategy predicated upon this view and suggest fine-tuning of arginase activity with natural inhibitors to preclude or halt the development of AD-related dementia.
My First Publication
Twenty-seven peer-reviewed papers now mark the milestones of my academic life. Most bear my name as first author, each the result of long months spent testing hypotheses, refining ideas, and shaping raw data into narrative. I have come to love the rhythm of writing: the careful construction of argument, the distillation of complexity into clarity, the small satisfaction of adding one more brick to the edifice of human knowledge.
With time, the process has grown familiar—the gauntlet of peer review, the delicate balance of ambition and realism when choosing a journal, the quiet discipline of revision. Yet one memory still stands apart, untouched by routine: my first publication.
It was early in my PhD when I began to notice subtle patterns in the data—persistent signals that resisted dismissal and challenged the field’s assumptions. The old phrase publish or perish echoed in my mind, but this felt different. Why consign the work to a modest journal when it might deserve something greater?
The submission consumed me. Every figure was polished, every sentence scrutinized until it felt like glass. I still remember the gravity of that final click—submit—a strange mixture of release and surrender. Then came the waiting. Weeks stretched into months, each new email a potential turning point, each delay an agony of uncertainty.
And then it arrived: Your article has been accepted for publication.
The words shimmered on the screen. In that instant, the months of labor, the countless revisions, the anxious refreshes of my inbox—all transformed into something radiant. My work had crossed the threshold. I was no longer merely a student of knowledge, but a contributor to it.
Today, the process flows with less drama. The writing feels more natural, the satisfaction quieter, more professional. Yet that first acceptance remains crystalline in memory—the moment I discovered that curiosity, sharpened into discipline, could create something that would outlast me. That email was not only a validation of findings; it was the opening note of a life dedicated to inquiry.
“The only true wisdom is in knowing you know nothing.”
― Socrates
Connect
Explore science, creativity, and shared passions here.
© 2025. All rights reserved.